Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q3 EPS Loss of $0.10

Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $584 thousand versus the consensus estimate of $500 thousand.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Morgan Stanley
• Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
• H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)